Dexamethasone News and Research

RSS

Single injection could treat pain days, weeks, maybe even months

Researchers at Children's Hospital Boston have developed a slow-release anesthetic drug-delivery system that could potentially revolutionize treatment of pain during and after surgery, and may also have a large impact on chronic pain management

15 Apr 2009

Cigarette smoke changes the immune response to bacteria - culprit behind COPD exacerbations

Smoking cigarettes is not only the principle cause of chronic obstructive pulmonary disease (COPD), but it may change the body's immune responses to bacteria that commonly cause exacerbations of the disease, according to new research in a mouse model.

8 Apr 2009

$Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma$

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.

10 Dec 2008

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.

10 Dec 2008

Drug combo improves or stabilizes disease for relapsed multiple myeloma patients

Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment.

10 Dec 2008

Novel therapeutic approaches for various forms of thrombocytopenia

Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, were presented December 6 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Glucocorticoids may cause damage in the brain

A class of drugs that are used in premature infants to treat chronic lung damage can cause damage in the brain.

17 Nov 2008

Visualizing asthma-causing immune cells at work

Immune cells known as eosinophils have a central role in causing asthma.

7 Nov 2008

Scientists use nanoscale polymer films to control drug delivery

Using nanotechnology, scientists from UCLA and Northwestern University have developed a localized and controlled drug delivery method that is invisible to the immune system, a discovery that could provide newer and more effective treatments for cancer and other diseases.

23 Jan 2008

Stem cells make bone marrow cancer resistant to treatment

Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatments.

15 Jan 2008

Velcade, lenalidomide and dexamethasone combo show promise for multiple myeloma

A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.

13 Dec 2007

New therapeutic options for newly diagnosed multiple myeloma patients

Mayo Clinic researchers presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy.

10 Dec 2007

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial

Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma.

10 Dec 2007

Multiple myeloma clinical trial shows distinct survival benefit with lower dose of steroids

Results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03, for multiple myeloma, showing significantly better overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone, were reported today by S. Vincent Rajkumar, M.D. at the American Society of Hematology's annual meeting.

10 Dec 2007

Oral drug sets a new survival standard for bone marrow cancer

Findings from two large, international clinical trials show "unprecedented" survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow.

21 Nov 2007

Lenalidomide - dexamethasone combination effective against multiple myeloma

Pairing a new thalidomide derivative with a steroid slows progress of multiple myeloma, an incurable bone marrow cancer, and prolongs the lives of patients who have relapsed from previous treatment, researchers report in the Nov. 22 New England Journal of Medicine.

21 Nov 2007

Prazosin curbs brain damage from post-traumatic stress disorder

A drug used to treat high blood pressure and enlargement of the prostate may protect the brain from damage caused by post-traumatic stress disorder, Alzheimer's disease, depression and schizophrenia.

6 Nov 2007

Large dose dexamethasone plays important roles in severe acute pancreatitis

Severe acute pancreatitis (SAP) is a fatal systemic disease featuring acute onset, serious conditions, high incidence of complications and 20 - 30% mortality, mainly due to multiple organ failure at its early stage.

5 Nov 2007

Anti-leukemia drug dexamethasone increases patient fatigue

The anti-leukemia drug dexamethasone contributes to a relentless fatigue and poor quality of sleep in children undergoing treatment for acute lymphoblastic leukemia (ALL), according to a new study from St. Jude Children's Research Hospital.

2 Nov 2007

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Celgene International Sarl has announced that it's oral cancer drug, Revlimid (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

5 Sep 2007